Voltage-dependent calcium channel Inhibitors
1 drugsAbout Voltage-dependent calcium channel
Voltage-dependent calcium channels (VDCCs) are transmembrane proteins that mediate calcium influx into excitable cells upon membrane depolarization. This influx triggers intracellular processes like muscle contraction, neurotransmitter release, and hormone secretion.
VDCCs are important drug targets, particularly in cardiovascular disease. Currently, there is no genetic evidence data available linking VDCCs to specific diseases.
There is one FDA-approved drug, AZOR (COSETTE), targeting VDCCs for cardiovascular indications. AZOR is a small molecule approved in 2007.
Top Voltage-dependent calcium channel Drugs
COSETTE is the only company with an approved drug targeting VDCCs.
The lack of competitors suggests a high barrier to entry or an untapped market opportunity.
Voltage-dependent calcium channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Voltage-dependent calcium channel, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Voltage-dependent calcium channel Clinical Trials 111 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Voltage-dependent calcium channel. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 22 | 19 | 1 | 2 | 95% |
| Phase 2 | 15 | 12 | 1 | 2 | 92% |
| Phase 3 | 28 | 21 | 5 | 2 | 81% |
| Phase 4 | 46 | 28 | 10 | 8 | 74% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Voltage-dependent calcium channel Drug Approval Timeline (2007 - 2007)
The first and only drug, AZOR, was approved in 2007.
The absence of recent approvals indicates potential saturation or a need for innovative approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 69 (27 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Voltage-dependent calcium channel. A trial counts if an approved drug acting on Voltage-dependent calcium channel is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.